The correlation between pregnancy, disease activity and adverse pregnancy outcomes in patients with systemic lupus erythematosus

被引:1
|
作者
Cetin, Cigdem [1 ,4 ]
Sarac-Sivrikoz, Tugba [2 ]
Ates-Tikiz, Muege [2 ]
Zarali, Sibel [1 ]
Ersoy, Aysenur [3 ]
Yalcinkaya, Yasemin [1 ]
Gul, Ahmet [1 ]
Inanc, Murat [1 ]
Has, Recep [2 ]
Kalelioglu, Ibrahim [2 ]
Artim Esen, Bahar [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkiye
[2] Istanbul Univ, Istanbul Fac Med, Dept Obstet & Gynecol, Div Perinatol, Istanbul, Turkiye
[3] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkiye
[4] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Rheumatol, TR-34093 Istanbul, Turkiye
关键词
systemic lupus erythematosus; pregnancy; disease activity; adverse pregnancy outcome; damage index; FETAL OUTCOMES; SLE PATIENTS; HYDROXYCHLOROQUINE; NEPHRITIS; FLARES; PREDICTORS; PUERPERIUM; DIAGNOSIS; IMPACT; INDEX;
D O I
10.1177/09612033231208844
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: In this study, our pregnant systemic lupus erythematosus (SLE) cohort, which was under medical surveillance of both our Rheumatology and Obstetrics departments, was analyzed. We intended to determine the effects of pregnancy on disease activity and the correlation between disease flares and adverse pregnancy outcomes.Methods: One hundred sixty eight pregnancy data involving 136 patients with SLE were examined. Cumulative clinical, laboratory, and serological parameters were described. Disease activity and flares were calculated using the systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) in the pre/postpartum periods and the SLEPDAI in the three trimesters of pregnancy. Patients with a SLEDAI-2K or SLEPDAI >= 4 were classified as "active." Patients with lupus low disease activity state (LLDAS) during each of these periods were identified.Fetal/neonatal death, premature birth due to pre-eclampsia, eclampsia or hemolysis, elevated Liver enzymes (HELLP) syndrome, and neonates small for gestational age were determined as adverse pregnancy outcomes (APO).Results: Out of 168 pregnancies, there were 60 (35.7%) pregnancies with flares covering the pregnancy and 6 months of postpartum period. The mean SLEDAI in the 6 months postpartum period was significantly higher compared to mean disease activity during pregnancy (p < .05). Of all pregnancies, 132 (78.6%) were in LLDAS during pregnancy. Comparison of the frequency of severe postpartum flares in patients who were in LLDAS during pregnancy revealed a lower percentage of flares compared to those who were not in the LLDAS group (11 vs 29%, p < .05). APO was observed in 33.9% of 168 pregnancies. The mean SLEPDAI score was significantly higher in APO+ pregnancies than in APO- pregnancies (4.9 +/- 6.1 vs 2.8 +/- 4.9, p = .002). Comparison of SLICC damage score between APO - and + pregnancies revealed a significantly higher score in APO+ pregnancies (1.8 +/- 2.1 vs 0.8 +/- 1.3, p = .001).Conclusion: Postpartum six-month period appears to have the highest risk for disease flares during SLE pregnancies. Disease activity during pregnancy increases the risk of APO. In order to achieve a positive pregnancy outcome and lower maternal morbidity, regular follow-up of patients is necessary.
引用
收藏
页码:1509 / 1517
页数:9
相关论文
共 50 条
  • [1] THE CORRELATION BETWEEN PREGNANCY, DISEASE ACTIVITY AND ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Cetin, C.
    Sarac-Sivrikoz, T.
    Ates-Tikiz, M.
    Torun, E. S.
    Zarali, S.
    Yalcinkaya, Y.
    Gul, A.
    Inanc, M.
    Ocal, M. L.
    Kalelioglu, I.
    Artim-Esen, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 660 - 660
  • [2] The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
    Cetin, Cigdem
    Sivrikoz, Tugba Sarac
    Tikiz, Muge Ates
    Torun, Ege Sinan
    Zarali, Sibel
    Yalcinkaya, Yasemin
    Gul, Ahmet
    Inanc, Murat
    Ocal, Mahdume Lale
    Kalelioglu, Ibrahim
    Esen, Bahar Artim
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [4] Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus
    Sieiro Santos, Cristiana
    Moriano Morales, Clara
    Alvarez Castro, Carolina
    Gonzalez Fernandez, Ismael
    Diez Alvarez, Elvira
    [J]. MUSCULOSKELETAL CARE, 2022, 20 (04) : 917 - 925
  • [5] ADVERSE PREGNANCY OUTCOMES AND ASSOCIATED FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Zhan, Z.
    Chen, D.
    Yang, Y.
    Liang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 318 - 318
  • [6] RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Cetin, C.
    Sarac-Sivrikoz, T.
    Ates-Tikiz, M.
    Torun, E. S.
    Ersoy, A.
    Yalcinkaya, Y.
    Gul, A.
    Inanc, M.
    Ocal, M. L.
    Kalelioglu, I.
    Artim-Esen, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1038 - 1038
  • [7] Low Lupus Disease Activity State (LLDAS) and Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE)
    Meilleur, Shannon
    Vinet, Evelyne
    Bernatsky, Sasha
    Grenier, Louis-Pierre
    Kalache, Fares
    Pineau, Christian
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1125 - 1125
  • [8] Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes
    Tedeschi, Sara K.
    Guan, Hongshu
    Fine, Alexander
    Costenbader, Karen H.
    Bermas, Bonnie
    [J]. CLINICAL RHEUMATOLOGY, 2016, 35 (07) : 1725 - 1732
  • [9] Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes
    Sara K. Tedeschi
    Hongshu Guan
    Alexander Fine
    Karen H. Costenbader
    Bonnie Bermas
    [J]. Clinical Rheumatology, 2016, 35 : 1725 - 1732
  • [10] Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
    Palma dos Reis, Catarina R.
    Cardoso, Goncalo
    Carvalho, Carolina
    Nogueira, Isabel
    Borges, Augusta
    Serrano, Fatima
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2020, 59 (03) : 287 - 294